Net Worth of Integrity Biosolutions LLC reflects the company’s steady growth since its founding in the life sciences sector. The firm focuses on contract development and manufacturing for biopharma clients, building a reputation for reliability and technical depth.
As a privately held entity, detailed financial disclosures are limited, yet industry analysts track key metrics that signal market position and valuation. The summary below captures the most relevant indicators for investors and partners evaluating Integrity Biosolutions today.
| Company Name | Incorporation State | Primary Service Line | Reported Net Worth Range (USD) | Data Season |
|---|---|---|---|---|
| Integrity Biosolutions LLC | Delaware | Biopharma CDMO | $18M – $32M | Q2 2024 |
| Founding Year | 2016 | Revenue Segment | $12M – $18M | 2023 |
| Headquarters | Massachusetts | Major Clients | 3 mid-size biotechs | Reference Period |
| Ownership Structure | Private | Employee Count | 42 FTEs | Latest Audit |
Operational Scale And Facility Capabilities
Integrity Biosolutions operates from a single GMP-compliant facility designed to handle multi-product campaigns under strict quality controls. The site is organized into suites for aseptic filling, lyophilization, and analytical testing, which together enable end-to-end project execution.
Process validation suites support vial and cartridge filling, while cold chain arrangements ensure stability through critical phases. By aligning equipment design with client specifications, the company reduces transfer risks and accelerates technology readiness.
Quality Systems And Regulatory Compliance
The firm’s quality management system is ISO 13485 and ISO 9001 certified, with alignment to FDA and EMA expectations. Document control, change control, and deviation management workflows are maintained electronically to ensure traceability across batches.
Regular internal audits and management reviews identify improvement actions, while external audits from prime sponsors validate compliance. This layered oversight helps mitigate regulatory risk and supports faster commercial approvals.
Market Position And Growth Strategy
Integrity Biosolutions targets niche biologic products where flexible capacity and rapid turnaround are decisive. Its client mix includes early-phase developers and established firms outsourcing late-phase fills and finishes.
Geographic proximity to major research hubs enhances collaboration, and the company leverages this network to secure long-term service agreements. Strategic investments in analytical instrumentation and automation reinforce its competitive moat.
Strategic Roadmap And Long Term Value Drivers
Management prioritizes facility upgrades, talent acquisition, and expanded service offerings to unlock higher-margin work. Focused execution on these levers is expected to strengthen the net worth of integrity biosolutions llc over the next growth cycle.
- Invest in lyophilization capacity to capture niche product demand
- Expand analytical testing in-house to reduce client turnaround times
- Build strategic partnerships with regional biotech clusters
- Maintain strict compliance regimes to support premium pricing
FAQ
Reader questions
What services does Integrity Biosolutions provide under its contract development model?
The company offers formulation development, analytical method validation, aseptic fill-finish, lyophilization, stability studies, and regulatory filing support on a project or subscription basis.
How does the firm ensure data integrity and compliance for sponsor products?
Through electronic batch record systems, controlled document versions, trained personnel, and periodic third-party audits, Integrity Biosolutions maintains cGMP compliance and protects sponsor data.
What is the typical lead time for a clinical trial material campaign? Standard lead time ranges from 10 to 16 weeks from receipt of drug substance to final release, depending on product complexity, analytical requirements, and fill-finish volume. Can the facility scale up for commercial manufacturing without major requalification?
Equipment is designed with modular capacity and scalability in mind, allowing scale-up within validated ranges while minimizing requalification efforts and time to market.